Atossa Therapeutics

Muscles need more than strength to keep working. They need protection from the wear and tear of everyday movement.

In Duchenne muscular dystrophy (DMD), the body lacks functional dystrophin, a protein that helps protect muscle fibers. Over time, this leads to progressive muscle weakness and can affect the heart and lungs.

Atossa Therapeutics ($ATOS) is investigating (Z)-endoxifen in preclinical research exploring potential approaches to DMD.

Learn more: bit.ly/4iBV7KX

Atossa Therapeutics reports third quarter 2026 financial results and provides a corporate update, including anticipated FDA IND clearance for (Z)-endoxifen in Duchenne Muscular Dystrophy and McCune-Albright Syndrome by early 2027. $ATOS

Read more: bit.ly/4zhaFdt

Behind every cancer diagnosis is a person navigating uncertainty, difficult decisions and a life that may suddenly feel different. There are families waiting for news, caregivers offering support and patients finding their own way forward.

This #NationalCancerAwarenessDay, we recognize everyone whose life has been touched by cancer. Every experience deserves compassion, support and continued hope for progress.

ICYMI: Atossa Therapeutics CEO Dr. Steven Quay (@quay_dr) joined leaders from Novo Nordisk, UCLA and Mass General Brigham at #ARDD2026 to discuss clinical trial design and regulatory pathways for therapies targeting diseases of aging.

The panel explored surrogate endpoints, age-related comorbidities and patient-relevant measures of function, emphasizing the importance of connecting biomarkers to outcomes that people can feel. $ATOS

Watch the panel: youtube.com/watch?v=4NGbXQ…

A potential treatment starts with understanding how a compound works.

(Z)-endoxifen is the active form of a major tamoxifen metabolite. Unlike tamoxifen, it does not need to be converted by the liver to become the active compound.

Atossa Therapeutics ($ATOS) is studying its potential across breast cancer and selected rare diseases. Explore the science: bit.ly/4pH8kop